WESTBROOK, Maine, Feb. 1, 2018 /PRNewswire/ —

  • Achieves revenue growth in Q4 of 14% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 15% reported and 13% organic
  • Reports unprecedented 3,650 premium instrument placements in Q4, representing 15% year-over-year growth, supported by 25% growth in Catalyst® placements and 37% growth in SediVue Dx® placements to 747 units
  • Delivers full year diluted EPS of $2.94, including $31 million or a $0.34 per share one-time charge related to U.S. Tax Reform. Full year 2017 EPS increased 20% year over year on a reported basis and 21% on a comparable constant currency basis
  • Increases 2018 revenue guidance by $65 million to $2,205 million$2,245 million, reflecting expected reported revenue growth of 12% – 14% and organic revenue growth of 9.5% – 11.5%
  • Raises 2018 EPS outlook range by $0.55 from the midpoint of prior guidance to $4.04$4.18, reflecting expectations for continued strong operating performance, a lower effective tax rate related to U.S. Tax Reform, and benefits from foreign exchange 

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reports revenues of $506 million for the fourth quarter of 2017, an increase of 14% compared to the prior year period on a reported basis and 12% on an organic basis. Fourth quarter results were supported by accelerated gains in Companion Animal Group (“CAG”) Diagnostics recurring revenue, and broad-based strength across the IDEXX portfolio and regions. Earnings per diluted share (“EPS”) were $0.43 on a reported basis for the fourth quarter, reflecting a decline of 26% year over year, burdened with a one-time negative impact of $0.34 per share related to the enactment of the 2017 Tax Cuts and Jobs Act (“U.S. Tax Reform”), due to the deemed repatriation of the Company’s foreign profits, net of the remeasurement of deferred taxes at the lower enacted corporate tax rate.  Normalizing for this one-time negative tax impact, and for a $0.07 per share benefit from other tax items, EPS growth was 19% on a comparable constant currency basis in the fourth quarter.  

Revenue for the full year of $1,969 million increased 11% on a reported basis and 10% on an organic basis, driven by 13% reported and organic growth in global CAG Diagnostics recurring revenue. For the full year 2017, EPS of $2.94 increased 20% on a reported basis and 21% on a comparable constant currency basis, supported by a reported 130 basis points of operating margin improvement, or 140 basis points on a constant currency basis.

Based on its continued momentum, strong 2017 performance and favorable foreign exchange rate changes, the Company is raising its full year 2018 revenue growth outlook to 12% – 14% on a reported basis and 9.5% – 11.5% on an organic basis.  This updated outlook includes an estimated $10 million of revenue benefit from the implementation of ASU 2014-09, Revenue from Contracts with Customers (the “New Revenue Standard”), or approximately 0.5% contribution to the organic revenue growth rate. The Company is also increasing its EPS guidance range to $4.04$4.18 per share, an increase of $0.55 at the midpoint of prior guidance, reflecting approximately $0.06 per share in incremental benefits from strong operating profit performance trends, $0.10 of additional EPS related to updated foreign exchange assumptions, and $0.39 per share in benefits related to lower effective U.S. tax rates. This EPS outlook is consistent with the Company’s goals for constant currency operating margin improvement of 75 – 125 basis points. This outlook incorporates expectations for an incremental $10 million in operating expense investments in innovation and employees, and $5 million of additional capital investment, resulting from the opportunity presented by U.S. Tax Reform.

“Around the world, we’re seeing sustained, positive momentum in our markets, as the pet-human bond continues to strengthen, the appropriate use of diagnostics in the delivery of pet care gains further traction, and our exceptional commercial teams collaborate with veterinarians to support their practices’ growth with IDEXX’s unique diagnostic and software solutions,” said Jonathan Ayers, the Company’s Chairman and Chief Executive Officer.

“Our CAG Diagnostics recurring revenue grew 13% organically in the quarter. This growth was fueled by our continued expansion of the global installed base of premium instruments, up 20% year over year, including a remarkable 29% increase internationally and very strong 14% increase in North America. We had an unprecedented number of quarterly Catalyst placements worldwide, up 25% versus fourth quarter 2016, including 25% growth in Catalyst placements at new and competitive accounts in North America.

“The outlook for the year ahead looks exceptional, driven by continued strong growth in our CAG Diagnostics recurring revenues, and our continued introduction of advanced innovation to veterinary practices globally with our IDEXX SDMA® on a slide, fully launched in North America on January 16th, and SNAP® Fecal DxTM for the North American market, expected to be launched this coming summer.

“With great runway ahead, and building from a strong 2017 performance with the further tailwind of U.S. Tax Reform, we’re pleased to be raising our revenue and earnings outlook for 2018, continuing to deliver on our long-term financial goals.  With the opportunity presented by U.S. Tax Reform, we are augmenting investments in software, data and related innovation.  We will also be supporting our U.S. employees by raising the Company’s match for our 401(k) retirement plan, where we have tremendous U.S. employee participation.”

Fourth Quarter Performance Highlights

Fourth quarter revenue increased 14% to $506 million, benefited by a 2% favorable foreign exchange impact. EPS for the quarter was $0.43, net of a $0.34 per share one-time charge related to the enactment of U.S. Tax Reform, $0.06 per share in benefit from share-based compensation accounting adoption and less than $0.01 in discrete tax benefit from the expected utilization of foreign tax credits.

Companion Animal Group

CAG generated 14% reported and 12% organic revenue growth for the quarter, supported by CAG Diagnostics recurring organic revenue growth of 13%, with consistent strong growth in U.S. and international regions. Veterinary software services and diagnostic imaging systems revenue growth was strong, at 14% on a reported basis and 13% on an organic basis. 

  • Reference laboratory diagnostic and consulting services revenue grew 15% on a reported and 12% on an organic basis, reduced by approximately 1% related to fewer equivalent days. These results were driven by double-digit organic growth in the U.S., supported by strong organic volume gains with existing customers, solid net price realization and net customer additions. International reference lab organic revenue growth was also solid in the quarter, driven by gains in the European region.
  • IDEXX VetLab® consumables reported revenue grew 16% and organic revenue grew 14%, propelled by an expanding premium instrument base in U.S. and international markets.  IDEXX VetLab premium diagnostic instrument placements grew 15% to a record number of 3,650, including 1,863 Catalyst placements, reflecting a 25% increase year over year, 1,040 premium hematology instruments and a record number of 747 IDEXX SediVue Dx analyzer placements.
  • Rapid assay products generated strong revenue growth of 11% reported and 10% organic, benefitted by approximately 1%, due to favorable international distributor inventory changes, partially offset by fewer equivalent days. This continued solid growth was supported by volume growth in SNAP 4Dx® Plus Test and specialty SNAP tests, as well as continued progress in regaining share in first generation products in the U.S.

Livestock, Poultry and Dairy (“LPD”)

LPD delivered 13% reported and 8% organic revenue growth for the quarter, ahead of the Company’s expectations. The major drivers of this growth were higher than projected year-end government program and distributor ordering, as well as solid gains in recurring revenues, supported by growth of our pregnancy testing platform. These positive factors were partially offset by continued pressure on dairy and swine markets in China, which have constrained emerging market growth.

Water

Water achieved strong revenue growth of 19% on a reported basis and 16% on an organic basis in the fourth quarter, benefited by favorable comparisons to prior year channel inventory adjustments in advance of our go-direct initiative in Brazil. Excluding this impact, Water organic revenue growth is estimated at approximately 9% in the quarter, supported by continued solid volume growth in our core Colilert® franchise across major regions and net price realization.

Gross Profit and Operating Profit

Gross profits increased 13%, and gross margin decreased slightly to 53.8% from 54.3% in the prior year period. Constant currency gross margin was 54.0% for the quarter, 30 basis points lower than fourth quarter 2016, as continued solid net price and productivity gains were offset by investments in lab capacity, operations and IT; relatively higher year-over-year LPD and Water costs; as well as relatively lower average instrument margins, which were related to strong international growth resulting in lower average instrument prices.

Operating margins were 19.3% in the quarter, 40 basis points higher than the prior year period operating margin of 18.9%, on both a reported and constant currency basis, reflecting benefits from strong revenue gains.

2018 Financial Outlook

The Company is increasing its 2018 revenue outlook by $65 million to $2,205 million$2,245 million, or reported growth of 12% – 14%, reflecting its strong 2017 performance, an estimated $10 million benefit from the New Revenue Standard, and an estimated $35 million benefit related to updated assumptions for foreign exchange rates, as noted below. At these new rate assumptions compared to market rates in 2017, we estimate that the effect of the weaker U.S. dollar will benefit 2018 reported revenue growth by approximately 2.0% – 2.5%, EPS growth by approximately 4%, and EPS by an estimated $0.12 per share, including the net impact from projected hedge losses of approximately $7 million in 2018.

We are increasing our 2018 EPS outlook to $4.04$4.18 per share, an increase of $0.55, or targeted growth of 37% – 42% on a reported basis and 29% – 33% on a comparable constant currency basis. The Company is projecting free cash flow at approximately 80% – 85% of net income in 2018, including an estimated 15% impact related to $50 million of incremental capital spending related to our Westbrook, Maine headquarters expansion and the relocation and expansion of our core laboratory in Germany, in addition to approximately $5 million in additional funding of our capital plan to support incremental growth initiatives. For 2018, the Company projects capital spending of approximately $140 million.

The updated guidance for 2018 reflects recent trends, and assumes that the value of the U.S. dollar relative to other currencies will be: the euro at $1.22; the British pound at $1.40; the Canadian dollar at $0.79; the Australian dollar at $0.78; the Japanese yen at ¥111; the Chinese renminbi at RMB 6.45; and the Brazilian real at R$3.21 to the U.S. dollar for the full year of 2018.

The Company provides the following updated guidance for 2018:

Amounts in millions except per share data and percentages

Guidance Range

Growth Definition

Year-over-year
Growth

Revenue

$2,205 – $2,245

Reported

12% – 14%

Organic Revenue Growth

9.5% – 11.5%

EPS

$4.04 – $4.18

Reported

37% – 42%

Constant Currency

Comparable Constant Currency

42% – 46%

29% – 33%

Operating Cash Flow

~120% – 125% of net income

Free Cash Flow

~80% – 85% of net income

Capital Expenditures

~$140 million

We expect an effective tax rate of 20.0% – 21.0%, including recurring benefits related to the enactment of U.S. Tax Reform, and approximately 300 basis points related to the accounting standard for the projected tax benefit of employee share-based compensation. We are projecting a reduction in weighted average shares outstanding of approximately 1.0% – 1.5%, and interest expense, net of interest income, of approximately $35 million$36 million, reflecting current and projected borrowings.

For a quick-reference snapshot of the Company’s quarterly and full year 2017 performance, please visit www.idexx.com/investors.

Conference Call and Webcast Information

IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (Eastern) to discuss its fourth quarter and full year 2017 results and management’s outlook. To participate in the conference call, dial 1-800-230-1092 or 1-612-288-0337 and reference confirmation code 443123. An audio replay will be available through Thursday, February 8, 2018 by dialing 1-800-475-6701 or 1-320-365-3844 and referencing replay code 443123.

The call will also be available via live or archived webcast on the IDEXX Laboratories’ website at www.idexx.com/investors and will be available for one year.

IDEXX Laboratories, Inc. logo. (PRNewsFoto/IDEXX Laboratories, Inc.)

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 7,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements 

This earnings release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are included above under “2018 Financial Outlook” and elsewhere and can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “projected”, “should,” and similar words and expressions. Our forward-looking statements include statements relating to our product launches; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impacts of U.S. Tax Reform and New Revenue Standard; projected operating expense investments, including with respect to employee benefits; projected impact of foreign currency exchange rates and instrument placement program mix; and projected operating margins and expenses, capital expenditures, losses from foreign currency hedging transactions, tax and EPS benefits from share-based compensation arrangements, discrete tax benefits related to foreign tax credits, effective tax rates, weighted average shares outstanding and interest expense. These statements are based on management’s expectation of future events as of the date of this earnings release. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. A description of the risks and uncertainties that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s 2016 Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission available at www.sec.gov.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America (“GAAP”), otherwise referred to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Constant currency – Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates.  These estimated currency changes increased fourth quarter 2017 revenue growth by 2%, increased gross profit growth by 2%, reduced gross profit margin growth by 20 basis points, had an immaterial impact on operating profit margin growth, and increased EPS growth by 2%; increased full year 2017 revenue growth by approximately 0.3%, reduced operating profit margin growth by 10 basis points, and reduced 2017 EPS growth by approximately 1%; are expected to increase projected full year 2018 revenue growth by approximately 2% – 2.5%, increase projected operating profit margin growth by approximately 20 basis points, and increase projected 2018 EPS growth by approximately 4%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months and year ended December 31, 2017.

Growth and organic revenue growth – All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that excludes the impact of changes in foreign currency exchange rates and revenue from business acquisitions. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months and year ended December 31, 2017.  See the constant currency note above for the impacts of estimated currency changes to the projected 2018 organic revenue growth for the Company.  The percentage change in revenue resulting from acquisitions represents incremental revenues attributable to acquisitions that have occurred since the beginning of the prior year period. For the calculation of projected 2018 organic revenue growth, the impacts of revenue from acquisitions is immaterial.

Comparable constant currency EPS growth – Comparable constant currency EPS growth is a non-GAAP financial measure that excludes the impact of the Company’s adoption of share-based compensation accounting change (ASU 2016-09) for the periods after its adoption on January 1, 2017, a one-time negative impact related to U.S. Tax Reform, and a discrete tax benefit related to the expected utilization of foreign tax credits.  The adoption of ASU 2016-09 increased fourth quarter 2017 EPS growth by 10%, increased full year 2017 EPS growth by 13%, and is expected to reduce projected full year 2018 EPS growth by approximately 5%.  A one-time negative impact related to the enactment of the Tax Cuts and Jobs Act for the fourth quarter, due to the deemed repatriation of the Company’s foreign profits, net of the remeasurement of deferred taxes at the lower enacted corporate tax rate, reduced fourth quarter 2017 EPS growth by 59%, reduced full year 2017 EPS growth by 14%, and is expected to increase projected full year 2018 EPS growth by approximately 12%.  A discrete tax benefit related to the expected utilization of foreign tax credits increased fourth quarter 2017 EPS growth by 2%, increased full year 2017 EPS growth by 2%, and is expected to reduce projected full year 2018 EPS growth by approximately 1%. These impacts and those described in the constant currency note above reconcile reported EPS growth to comparable constant currency EPS growth for the Company.

Free cash flow – Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, including tax benefits attributable to share-based compensation, reduced by the Company’s investments in property and equipment.  Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. See the supplementary analysis of results below for our calculation of free cash flow for the years ended December 31, 2017 and 2016.  Since adoption of ASU 2016-09 in 2017, the tax benefit from share-based compensation is included in cash generated from operations and will no longer be an adjustment in our free cash flow calculation.  To estimate projected 2018 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of ~$140 million.

Debt to Adjusted EBITDA (Leverage Ratios) – Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures.  Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization and share-based compensation.  Management believes that using Adjusted EBITDA, gross debt and net debt in the Adjusted EBITDA ratio is a useful and recognized measure for evaluating financial leverage.  For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratio are calculated, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

 

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Operations

Amounts in thousands except per share data (Unaudited)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

December 31,

December 31,

2017

2016

2017

2016

Revenue:

Revenue

$506,121

$442,996

$1,969,058

$1,775,423

Expenses and Income:

Cost of revenue

233,647

202,370

871,676

799,987

Gross profit

272,474

240,626

1,097,382

975,436

Sales and marketing

90,539

80,605

354,294

317,058

General and administrative

55,318

50,778

220,878

207,017

Research and development

28,809

25,418

109,182

101,122

Income from operations

97,808

83,825

413,028

350,239

Interest expense, net

(8,122)

(6,698)

(31,971)

(28,393)

Income before provision for income taxes

89,686

77,127

381,057

321,846

Provision for income taxes

51,396

24,756

117,788

99,792

Net Income:

Net income

38,290

52,371

263,269

222,054

Less: Noncontrolling interest in subsidiary’s earnings

33

2

125

9

Net income attributable to stockholders

$38,257

$52,369

$263,144

$222,045

Earnings per share: Basic

$0.44

$0.59

$3.00

$2.47

Earnings per share: Diluted

$0.43

$0.58

$2.94

$2.44

Shares outstanding: Basic

87,427

89,294

87,769

89,732

Shares outstanding: Diluted

89,045

90,589

89,567

90,884

 

 


IDEXX Laboratories, Inc. and Subsidiaries

Selected Operating Information (Unaudited)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

December 31,

December 31,

2017

2016

2017

2016

Operating Ratios

Gross profit

53.8%

54.3%

55.7%

54.9%

(as a percentage of revenue):

Sales, marketing, general and administrative expense

28.8%

29.7%

29.2%

29.5%

Research and development expense

5.7%

5.7%

5.5%

5.7%

Income from operations 1

19.3%

18.9%

21.0%

19.7%

1Amounts presented may not recalculate due to rounding.

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Segment Information

Amounts in thousands (Unaudited)

Three Months Ended

Three Months Ended

December 31,

Percent of

December 31,

Percent of

2017

Revenue

2016

Revenue

Revenue:

CAG

$433,516

$379,539

Water

28,864

24,336

LPD

37,215

32,980

Other

6,526

6,141

Total

$506,121

$442,996

Gross Profit:

CAG

$230,876

53.3%

$201,354

53.1%

Water

19,609

67.9%

17,181

70.6%

LPD

20,957

56.3%

19,818

60.1%

Other

3,162

48.5%

3,562

58.0%

Unallocated Amounts

(2,130)

N/A

(1,289)

N/A

Total

$272,474

53.8%

$240,626

54.3%

Income from Operations:

CAG

$85,700

19.8%

$71,484

18.8%

Water

12,195

42.2%

10,838

44.5%

LPD

6,584

17.7%

6,249

18.9%

Other

1,562

23.9%

1,633

26.6%

Unallocated Amounts

(8,233)

N/A

(6,379)

N/A

Total

$97,808

19.3%

$83,825

18.9%

 

 

Twelve Months Ended

Twelve Months Ended

December 31,

Percent of

December 31,

Percent of

2017

Revenue

2016

Revenue

Revenue:

CAG

$1,703,377

$1,522,689

Water

114,395

103,579

LPD

128,481

126,491

Other

22,805

22,664

Total

$1,969,058

$1,775,423

Gross Profit:

CAG

$936,798

55.0%

$820,322

53.9%

Water

79,365

69.4%

71,878

69.4%

LPD

72,140

56.1%

73,801

58.3%

Other

11,388

49.9%

11,561

51.0%

Unallocated Amounts

(2,309)

N/A

(2,126)

N/A

Total

$1,097,382

55.7%

$975,436

54.9%

Income from Operations:

CAG

$363,557

21.3%

$301,342

19.8%

Water

50,616

44.2%

45,702

44.1%

LPD

16,464

12.8%

18,914

15.0%

Other

4,837

21.2%

884

3.9%

Unallocated Amounts

(22,446)

N/A

(16,603)

N/A

Total

$413,028

21.0%

$350,239

19.7%

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Three Months Ended

Percentage

Percentage

Organic

December 31,

December 31,

Dollar

Percentage

Change from

Change from

Revenue

Net Revenue

2017

2016

Change

Change

Currency

 Acquisitions

Growth 1

CAG

$433,516

$379,539

$53,977

14.2%

2.1%

0.4%

11.8%

     United States

278,396

250,395

28,001

11.2%

0.4%

10.8%

     International

155,120

129,144

25,976

20.1%

6.2%

0.4%

13.6%

Water

28,864

24,336

4,528

18.6%

2.5%

16.1%

     United States

13,125

12,493

632

5.1%

5.1%

     International

15,739

11,843

3,896

32.9%

5.6%

27.3%

LPD

37,215

32,980

4,235

12.8%

4.4%

8.4%

     United States

3,615

3,289

326

9.9%

9.9%

     International

33,600

29,691

3,909

13.2%

4.9%

8.3%

Other

6,526

6,141

385

6.3%

0.5%

5.8%

Total Company

$506,121

$442,996

$63,125

14.2%

2.2%

0.3%

11.7%

     United States

297,782

267,730

30,052

11.2%

0.4%

10.9%

     International

208,339

175,266

33,073

18.9%

5.7%

0.3%

12.9%

 

 

Three Months Ended

Percentage

Percentage

Organic

December 31,

December 31,

Dollar

Percentage

Change from

Change from

Revenue

Net CAG Revenue

2017

2016

Change

Change

Currency

 Acquisitions

Growth 1

CAG Diagnostics recurring revenue:

$359,765

$312,162

$47,603

15.2%

2.1%

0.4%

12.8%

IDEXX VetLab consumables

133,693

114,973

18,720

16.3%

2.2%

14.1%

Rapid assay products

46,224

41,539

4,685

11.3%

1.1%

10.2%

Reference laboratory diagnostic and consulting services

161,924

140,553

21,371

15.2%

2.2%

0.8%

12.2%

CAG Diagnostics services and accessories

17,924

15,097

2,827

18.7%

2.6%

16.1%

CAG Diagnostics capital – instruments

36,945

35,130

1,815

5.2%

3.3%

1.9%

Veterinary software, services and diagnostic imaging systems

36,806

32,247

4,559

14.1%

0.5%

0.9%

12.7%

Net CAG revenue

$433,516

$379,539

$53,977

14.2%

2.1%

0.4%

11.8%

1 See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts in thousands (Unaudited)

Twelve Months Ended

Percentage

Percentage

Organic

December 31,

December 31,

Dollar

Percentage

Change from

Change from

Revenue

Net Revenue

2017

2016

Change

Change

Currency

 Acquisitions

Growth 1

CAG

$1,703,377

$1,522,689

$180,688

11.9%

0.3%

0.2%

11.4%

     United States

1,125,364

1,017,065

108,299

10.6%

0.2%

10.5%

     International

578,013

505,624

72,389

14.3%

0.8%

0.4%

13.2%

Water

114,395

103,579

10,816

10.4%

0.3%

10.2%

     United States

55,482

52,852

2,630

5.0%

5.0%

     International

58,913

50,727

8,186

16.1%

0.6%

15.6%

LPD

128,481

126,491

1,990

1.6%

1.1%

0.5%

     United States

14,108

13,253

855

6.5%

6.5%

     International

114,373

113,238

1,135

1.0%

1.2%

(0.2%)

Other

22,805

22,664

141

0.6%

0.1%

0.5%

Total Company

$1,969,058

$1,775,423

$193,635

10.9%

0.3%

0.2%

10.4%

     United States

1,203,547

1,089,595

113,952

10.5%

0.2%

10.3%

     International

765,511

685,828

79,683

11.6%

0.8%

0.3%

10.5%

 

 

Twelve Months Ended

Percentage

Percentage

Organic

December 31,

December 31,

Dollar

Percentage

Change from

Change from

Revenue

Net CAG Revenue

2017

2016

Change

Change

Currency

 Acquisitions

Growth 1

CAG Diagnostics recurring revenue:

$1,451,701

$1,281,262

$170,439

13.3%

0.2%

0.3%

12.8%

IDEXX VetLab consumables

518,774

451,456

67,318

14.9%

0.3%

14.6%

Rapid assay products

205,309

189,122

16,187

8.6%

0.1%

8.5%

Reference laboratory diagnostic and consulting services

660,142

581,067

79,075

13.6%

0.2%

0.6%

12.8%

CAG Diagnostics services and accessories

67,476

59,617

7,859

13.2%

0.3%

12.9%

CAG Diagnostics capital – instruments

119,963

121,191

(1,228)

(1.0%)

0.6%

(1.6%)

Veterinary software, services and diagnostic imaging systems

131,713

120,236

11,477

9.5%

0.2%

0.5%

8.9%

Net CAG revenue

$1,703,377

$1,522,689

$180,688

11.9%

0.3%

0.2%

11.4%

1 See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Balance Sheet

Amounts in thousands (Unaudited)

December 31,

December 31,

2017

2016

Assets:

Current Assets:

Cash and cash equivalents

$187,675

$154,901

Marketable securities

284,255

236,949

Accounts receivable, net

234,597

204,494

Inventories

164,318

158,034

Other current assets

101,140

91,206

Total current assets

971,985

845,584

Property and equipment, net

379,096

357,422

Other long-term assets, net

362,335

327,698

Total assets

$1,713,416

$1,530,704

Liabilities and Stockholders’

Equity (Deficit):

Current Liabilities:

Accounts payable

$66,968

$60,057

Accrued liabilities

253,418

236,131

Line of credit

655,000

611,000

Deferred revenue

29,181

27,380

Total current liabilities

1,004,567

934,568

Long-term debt

606,075

593,110

Other long-term liabilities, net

156,616

111,239

Total long-term liabilities

762,691

704,349

Total stockholders’ equity (deficit)

(54,106)

(108,352)

Noncontrolling interest

264

139

Total stockholders’ equity (deficit)

(53,842)

(108,213)

Total liabilities and stockholders’ equity (deficit)

$1,713,416

$1,530,704

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Selected Balance Sheet Information (Unaudited)

December 31,

September 30,

June 30,

March 31,

December 31,

2017

2017

2017

2017

2016

Selected Balance Sheet Information: 

Days sales outstanding 1

41.7

43.4

41.7

42.4

42.1

Inventory turns 2

2.2

1.9

2.0

1.9

2.0

1 Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days.

2 Inventory turns represent inventory-related cost of product sales for the twelve months preceding each quarter-end divided by the inventory balance at the end of the quarter.

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Cash Flows

Amounts in thousands (Unaudited)

Years Ended

December 31,

December 31,

2017

2016

Operating:

Cash Flows from Operating Activities:

Net income

$263,269

$222,054

Non-cash charges

101,627

124,217

Changes in assets and liabilities

8,380

7,374

Tax benefit from share-based compensation arrangements

(14,702)

Net cash provided by operating activities

373,276

338,943

Investing:

Cash Flows from Investing Activities:

Purchases of property and equipment

(74,384)

(64,787)

Purchase of marketable securities

(334,164)

(227,894)

Proceeds from the sale and maturities of marketable securities

286,759

203,859

Acquisitions of intangible assets

(2,320)

Acquisitions of businesses, net of cash acquired

(14,579)

(1,964)

Net cash used by investing activities

(138,688)

(90,786)

Financing:

Cash Flows from Financing Activities:

Borrowings on revolving credit facilities, net

44,000

38,000

Repurchases of common stock

(282,565)

(304,086)

Debt issue costs

(56)

Proceeds from exercises of stock options and employee stock purchase plans

38,622

38,344

Shares withheld for statutory tax withholding on restricted stock

(8,073)

(4,372)

Payment of acquisition-related contingent consideration

(4,728)

Tax benefit from share-based compensation arrangements

14,702

Net cash used by financing activities

(208,016)

(222,196)

Net effect of changes in exchange rates on cash

6,202

(54)

Net increase in cash and cash equivalents

32,774

25,907

Cash and cash equivalents, beginning of period

154,901

128,994

Cash and cash equivalents, end of period

$187,675

$154,901

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Free Cash Flow

Amounts in thousands except per share data (Unaudited)

Years Ended

December 31,

December 31,

2017

2016

Free Cash Flow:

Net cash provided by operating activities

$373,276

$338,943

Financing cash flows attributable to tax benefits from share-based compensation arrangements

14,702

Investing cash flows attributable to purchases of property and equipment

(74,384)

(64,787)

Free cash flow 1

$298,892

$288,858

1 See Statements Regarding Non-GAAP Financial Measures, above.

 

 

IDEXX Laboratories, Inc. and Subsidiaries

Common Stock Repurchases

Amounts in thousands except per share data (Unaudited)

Three Months Ended

Twelve Months Ended

December 31,

December 31,

December 31,

December 31,

2017

2016

2017

2016

Shares repurchased in the open market

351

1,951

1,749

3,071

Shares acquired through employee surrender for statutory tax withholding

2

4

57

60

Total shares repurchased

353

1,955

1,806

3,131

Cost of shares repurchased in the open market

$54,977

$224,837

$270,297

$313,072

Cost of shares for employee surrenders

245

422

8,074

4,372

Total cost of shares

$55,222

$225,259

$278,371

$317,444

Average cost per share – open market repurchases

$156.57

$115.22

$154.51

$101.96

Average cost per share – employee surrenders

$156.44

$114.16

$142.55

$73.04

Average cost per share – total

$156.57

$115.22

$154.13

$101.40

 

 

Contact: Kerry Bennett, Investor Relations, 1-207-556-8155

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/idexx-laboratories-announces-fourth-quarter-and-full-year-2017-results-300591576.html

SOURCE IDEXX Laboratories, Inc.